Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How does sumatriptan perform in clinical practice?

C G Dahlöf1

  • 1Gothenburg Migraine Clinic, Sweden.

Cephalalgia : an International Journal of Headache
|October 1, 1995
PubMed
Summary

Sumatriptan significantly reduces migraine attack duration and improves work efficiency for many patients. However, adverse events like drowsiness and chest symptoms are common, and headaches may recur within 24 hours.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials.

Cephalalgia : an international journal of headache·2006
Same author

Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraine.

International journal of clinical practice·2005
Same author

Sumatriptan: pharmacological basis and clinical results.

Current medical research and opinion·2002
Same author

Sumatriptan injection and tablets in clinical practice: results of a survey of 707 migraineurs.

Headache·2001
Same author

Within-patient consistency of response of rizatriptan for treating migraine.

Neurology·2000
Same author

Rizatriptan in the treatment of migraine.

Clinical therapeutics·2000

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Migraine is a debilitating neurological disorder impacting millions globally.
  • Sumatriptan is a widely used medication for acute migraine treatment.

Purpose of the Study:

  • To evaluate patient-reported outcomes and experiences with sumatriptan treatment for migraine.
  • To assess the efficacy and adverse events associated with subcutaneous and oral sumatriptan.

Main Methods:

  • A telephone survey was conducted with 351 migraineurs (299 female, 52 male).
  • Data collected on cumulative experience with over 20,000 subcutaneous injections and 2,000 oral doses.
  • Patient-reported outcomes included attack duration, work efficiency, and adverse events.

Main Results:

  • Subcutaneous sumatriptan reduced attack duration from 38.4 hours to 2.3 hours; oral sumatriptan reduced it to 3.4 hours.
  • Work efficiency improved significantly to 76.3% on sumatriptan compared to 26.6% with other treatments.
  • Common adverse events included drowsiness (49%), chest symptoms (40%), and injection site reactions (37%).
  • Headache recurrence within 24 hours was reported by 78% of subcutaneous users.

Conclusions:

  • Sumatriptan is highly effective in alleviating migraine symptoms and improving daily functioning.
  • Patients frequently experience adverse events, necessitating careful consideration of treatment risks and benefits.
  • The short-lasting effect and recurrence of headache are important factors in sumatriptan's overall utility.

Related Experiment Videos